Effect of Intravenous Chemotherapy Regimen on Globe Salvage Success Rates for Retinoblastoma Based on Disease Class—A Meta-Analysis
Open Access
- 6 May 2021
- Vol. 13 (9), 2216
- https://doi.org/10.3390/cancers13092216
Abstract
To evaluate the relative efficacy of novel retinoblastoma treatments, eye classification-specific success rates for current standard-of-care intravenous chemotherapy regimens must be known. This meta-analysis included studies if: (1) patients received intravenous chemotherapy for retinoblastoma, (2) globe salvage data was reported, (3) only intravenous chemoreduction (with/without local consolidation) was used. The outcome measure was globe salvage success without need for salvage radiotherapy, subdivided by disease classification and chemotherapy regimen. Data from 27 studies (1483 eyes) were pooled. By Reese–Ellsworth classification, globe salvage rates were 85% (95%CI:73–92%) for Group I, 78% (95%CI:70–85%) for Group II, 68% (95%CI:56–78%) for Group III, 47% (95%CI:34–60%) for Group IV, and 35% (95%CI:26–45%) for Group V (Va: 35% [95%CI:21–54%]; Vb: 42% [95%CI:29–56%]; those without sub-classification: 31% [95%CI:19–47%]). By International Classification, globe salvage rates were 93% (95%CI:80–97%) for Group A, 83% (95%CI:73–89%) for Group B, 73% (95%CI:54–86%) for Group C, 40% (95%CI:31–51%) for Group D, and 19% (95%CI:5–50%) for Group E. Standard carboplatin-etoposide-vincristine out-performed two-drug regimens (odds ratio (OR) = 1.9 (95%CI:1.3–3.0) for Groups I-IV and OR = 2.1 (95%CI:1.3–3.4) for Group V; p = 0.002 for each). For eyes with diffuse vitreous seeds (Vb), an enhanced regimen out-performed standard chemotherapy (OR = 2.4 [95%CI:1.3–4.7]; p = 0.004). In conclusion, two-drug regimens were less effective for all eyes, whereas enhanced regimens were more effective for eyes with vitreous seeds. Novel therapies can now be compared to these baseline globe salvage rates.Keywords
Funding Information
- National Eye Institute (NIH/NEI K08EY027464)
- Research to Prevent Blindness (Career Development Award and Unrestricted Grant to the Vanderbilt Department of Ophthalmology)
This publication has 57 references indexed in Scilit:
- Intravenous and intra-arterial chemotherapy for retinoblastomaCurrent Opinion in Opthalmology, 2012
- Eye-Preserving Therapy in Retinoblastoma: Prolonged Primary Chemotherapy Alone or Combined with Local TherapyKorean Journal of Ophthalmology, 2010
- Published International Classification of Retinoblastoma (ICRB) Definitions Contain Inconsistencies—An Analysis of ImpactOphthalmic Genetics, 2009
- Survival with retinoblastoma in the USA: 1975-2004British Journal of Ophthalmology, 2008
- Clinical manifestations and treatment of retinoblastoma in KoreaBritish Journal of Ophthalmology, 2008
- Chemoreduction for Intraocular Retinoblastoma in MalaysiaJournal of Pediatric Hematology/Oncology, 2007
- Treatment of Retinoblastoma Patients With Chemoreduction Plus Local Therapy: Experience of the AC Camargo Hospital, BrazilJournal of Pediatric Hematology/Oncology, 2006
- Effect on Ocular Survival of Adding Early Intensive Focal Treatments to a Two-Drug Chemotherapy Regimen in Patients With RetinoblastomaAmerican Journal of Ophthalmology, 2005
- Conservative Therapy in Intraocular RetinoblastomaJournal of Pediatric Hematology/Oncology, 2005
- The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastomaInternational Journal of Clinical Oncology, 2004